What the business is, and whether it's a good one at a fair price.
Makes and sells generic pharmaceuticals — both prescription and over-the-counter — primarily in the United States, United Kingdom, rest of Europe and Canada, with manufacturing based in India, the UK and the USA. The US business drives the largest pull, supported by a $220M+ order book and approvals from the USFDA for molecules such as amide hydrochloride in pain, allergy, gastrointestinal and cough/cold categories; the Teva facility is ramping toward an INR 800 crores revenue target, currently trending at INR 560-600 crores. The UK business runs through the Relonchem subsidiary and is filing 4-5 products a month, stabilising after a period of pricing pressure on the back of new launches and currency support. European presence is being built via greenfield subsidiaries in Ireland and Canada, plus recent acquisitions of Netherlands-based QliniQ B.V. and Germany-based OTC distributor ABCnow GmbH to gain a direct front-end in those markets. FY26 consolidated revenue stood at INR 2,950.938 crores with an EBITDA margin of 23.16% and the company remained debt-free with INR 824.2 crores of cash. The biggest cost line is materials at 32.5% of revenue, followed by employees at 14.3% and other operating expenses at 22.1%, with R&D running at roughly 3% of sales to support the UK filing pace.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from MARKSANS PHARMA LIMITED's filed financials and exchange disclosures
MARKSANS PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol MARKSANS.
Yes. Over the trailing twelve months MARKSANS PHARMA LIMITED reported a net profit of ₹521 Cr on revenue of ₹3,172 Cr.
Yes. The dividend yield is 0.24% at the current price. It paid out 9% of its profit as dividend in FY26.
Effectively yes. It holds ₹605 Cr more cash than debt. Debt stands at 0.01× equity.
On trailing P/E, MARKSANS PHARMA LIMITED ranks 85 of 169 in Pharmaceuticals — cheaper than 50% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session MARKSANS PHARMA LIMITED moves 1.42% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by MARKSANS PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
